In an analysis of amyloid pathology in Alzheimer disease, we used an in situ approach to identify amyloid-β (Aβ) accumulation and oxidative damage to nucleic acids in postmortem brain tissue of the hippocampal formation from subjects with Alzheimer disease. When carboxyl-terminal-specific antibodies directed against Aβ40 and Aβ42 were used for immunocytochemical analyses, Aβ42 was especially apparent within the neuronal cytoplasm, at sites not detected by the antibody specific to Aβ-oligomer. In comparison to the Aβ42-positive neurons, neurons bearing oxidative damage to nucleic acids were more widely distributed in the hippocampus. Comparative density measurements of the immunoreactivity revealed that levels of intraneuronal Aβ42 were inversely correlated with levels of intraneuronal 8-hydroxyguanosine, an oxidized nucleoside (r = − 0.61, p b 0.02). Together with recent evidence that the Aβ peptide can act as an antioxidant, these results suggest that intraneuronal accumulation of non-oligomeric Aβ may be a compensatory response in neurons to oxidative stress in Alzheimer disease.
Introduction
Amyloid plaques, filamentous deposits of the amyloid-β (Aβ) peptide in the extracellular space, are defining lesions in Alzheimer disease (AD) brain. The accumulation of Aβ has been demonstrated to occur within neurons prior to extraneuronal deposition of Aβ plaques in patients with Down syndrome, an example of Alzheimer-type neurodegeneration (Gyure et al., 2001; Mori et al., 2002) , and in transgenic mouse models of AD (Wirths et al., 2001; Oddo et al., 2003; Lord et al., 2006; Oakley et al., 2006) . In AD, intraneuronal Aβ accumulation is evident at early-stages of the disease, including a prodromal stage characterized by mild cognitive impairment (MCI), and subsequently tends to decrease with the emergence of more prominent extraneuronal plaque pathology (Gouras et al., 2000; 2005) . Thus, intraneuronal Aβ accumulation is a significant early-stage event in AD.
In contrast, oxidative stress and oxidative cellular damage have been reported to be one of the earliest events in vulnerable neurons of AD (Nunomura et al., 2001; 2006; 2009) . Indeed, oxidative damage can be detected prior to the extraneuronal deposition of Aβ plaques in patients with Down syndrome (Nunomura et al., 2000) and in transgenic mice or knock-in mouse models of AD (Pratico et al., 2001; Anantharaman et al., 2006; Resende et al., 2008) . In AD and Down syndrome, oxidative damage is more prominent in patients with shorter disease duration and with lesser amount of extraneuronal deposition of Aβ (Cuajungco et al., 2000; Nunomura et al., 2000; 2001; 2004) , and is present in brains of subjects with MCI (Ding et al., 2005; Keller et al., 2005; Markesberry et al., 2005; Butterfield et al., 2006; 2007; Wang et al., 2006; Lovell and Makesberry, 2008) . Correspondingly, oxidative damage is a significantly early event in AD that is potentially correlated to the intraneuronal Aβ accumulation that characterizes the disease.
Experimentally, Aβ can be used to induce oxidative stress (Behl et al., 1994; Hensley et al., 1994; Schubert et al., 1995; Mark et al., 1997; Tabner et al., 2005) , and, on the other hand, oxidative stress can induce Aβ production and accumulation (Yan et al., 1995; Frederikse et al., 1996; Paola et al., 2000; Misonou et al., 2000; Tong et al., 2005; Tamagno et al., 2005; 2008; Shen et al., 2008) . However, whether Aβ accumulation is primary to oxidative stress or oxidative stress is primary to Aβ accumulation is yet undetermined in AD. In this study, we investigated the distribution of and relationship between the 
